Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP-671 monotherapy in gout or hyperuricemia
NCT04638543Phase 2Completed
- Sponsor
- Atom Therapeutics
- Start
- Nov 2020
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lingdolinurad in gout, hyperuricemia, sponsored by Atom Therapeutics. Started Nov 2020; status: completed.
02
Drugs
lingdolinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT04638543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638543.